<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280874</url>
  </required_header>
  <id_info>
    <org_study_id>RANDOM1</org_study_id>
    <nct_id>NCT04280874</nct_id>
  </id_info>
  <brief_title>Induction of Labor in Term Pregnancies With Unfavourable Cervix</brief_title>
  <acronym>RAND</acronym>
  <official_title>Comparison of Intracervical and Intravaginal Application of Prostaglandin E2 for Induction of Labour in Term Pregnancies With Unfavourable Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Merkur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Merkur</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized trial comparing two prostaglandin E2 (dinoprostone) agents
      used for labor induction in pregnant women with term pregnancies and unfavorable cervix.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized trial includes pregnant women with term pregnancies, indication
      for labor induction and an unfavorable cervix. These women are randomized into two groups:
      one group is induced using an intracervical prostaglandin E2 (PGE2, dinoprostone)
      formulation, the other using an intravaginal PGE2 formulation. Main outcome is time period
      between beginning of labor induction to delivery, and a reduction of four hours is considered
      clinically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>212 pregnant women are randomly assigned into 2 groups for application of one of two dinoprostone agents used for labor induction (intravaginal or intracervical dinoprostone)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>two dinoprostone agents are randomly applied and compared - one in patient's cervix and the other in vagina without the patient knowing which agent is applied</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time period between beginning of labor induction to delivery</measure>
    <time_frame>5 days</time_frame>
    <description>hours (difference of 4 hours or more is considered significant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of births within 24h of start of labor induction</measure>
    <time_frame>7 days</time_frame>
    <description>N (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of deliveries by caesarean section or instrumental deliveries</measure>
    <time_frame>7 days</time_frame>
    <description>N (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of uterus hyperstimulation</measure>
    <time_frame>7 days</time_frame>
    <description>N (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <condition>Prostaglandins Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>GROUP A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>106 randomly selected pregnant women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>106 randomly selected pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 0.5 MG</intervention_name>
    <description>0.5mg dinoprostone applied intracervically</description>
    <arm_group_label>GROUP A</arm_group_label>
    <other_name>PREPIDIL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly</intervention_name>
    <description>2mg dinoprostone applied intravaginally</description>
    <arm_group_label>GROUP B</arm_group_label>
    <other_name>PROSTIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  term pregnancies (&gt; 37 weeks gestation)

          -  unfavourable cervix (Bishop score &lt;6)

          -  indication for labor induction

          -  absence of uterine contractions

          -  reassuring cardiotocography

        Exclusion Criteria:

          -  ruptured membranes

          -  scar uterus (previous caesarean section or uterus surgery)

          -  pregnancy complications: intrauterine growth restriction; oligohydramnios,
             pre-eclampsia, non-reassuring/pathological cardiotocography, cholestasis in pregnancy,
             diabetes mellitus, multifetal pregnancy, breech presentation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Vince, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Hospital Merkur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <zip>1000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Merkur</investigator_affiliation>
    <investigator_full_name>Katja Vince</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dinoprostone</keyword>
  <keyword>Bishop score</keyword>
  <keyword>labor induction</keyword>
  <keyword>term pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

